Common lymphoid progenitor cells give rise to NK cells, as well as B-cells and T-cells. The biopsy of the patient in this case reveals Reed-Sternberg cells, indicating Hodgkin’s lymphoma, a cancer of B-cells. Platelets, monocytes, basophils, and erythrocytes, on the other hand, are derived from common myeloid progenitor cells.

Haematopoiesis: The Generation of Immune Cells

Haematopoiesis is the process by which immune cells are produced from haematopoietic stem cells in the bone marrow. These stem cells give rise to two main types of progenitor cells: myeloid and lymphoid progenitor cells. All immune cells are derived from these progenitor cells.

The myeloid progenitor cells generate cells such as macrophages/monocytes, dendritic cells, neutrophils, eosinophils, basophils, and mast cells. On the other hand, lymphoid progenitor cells give rise to T cells, NK cells, B cells, and dendritic cells.

This process is essential for the proper functioning of the immune system. Without haematopoiesis, the body would not be able to produce the necessary immune cells to fight off infections and diseases. Understanding haematopoiesis is crucial in developing treatments for diseases that affect the immune system.

In coeliac disease, the spleen may undergo atrophy and Howell-Jolly bodies may be observed in red blood cells. Histiocytosis X includes Letterer-Siwe disease, which involves the excessive growth of macrophages.

The Anatomy and Function of the Spleen

The spleen is an organ located in the left upper quadrant of the abdomen. Its size can vary depending on the amount of blood it contains, but the typical adult spleen is 12.5cm long and 7.5cm wide, with a weight of 150g. The spleen is almost entirely covered by peritoneum and is separated from the 9th, 10th, and 11th ribs by both diaphragm and pleural cavity. Its shape is influenced by the state of the colon and stomach, with gastric distension causing it to resemble an orange segment and colonic distension causing it to become more tetrahedral.

The spleen has two folds of peritoneum that connect it to the posterior abdominal wall and stomach: the lienorenal ligament and gastrosplenic ligament. The lienorenal ligament contains the splenic vessels, while the short gastric and left gastroepiploic branches of the splenic artery pass through the layers of the gastrosplenic ligament. The spleen is in contact with the phrenicocolic ligament laterally.

The spleen has two main functions: filtration and immunity. It filters abnormal blood cells and foreign bodies such as bacteria, and produces properdin and tuftsin, which help target fungi and bacteria for phagocytosis. The spleen also stores 40% of platelets, reutilizes iron, and stores monocytes. Disorders of the spleen include massive splenomegaly, myelofibrosis, chronic myeloid leukemia, visceral leishmaniasis, malaria, Gaucher’s syndrome, portal hypertension, lymphoproliferative disease, haemolytic anaemia, infection, infective endocarditis, sickle-cell, thalassaemia, and rheumatoid arthritis.

The presence of a Factor V Leiden mutation can lead to activated protein C resistance, which is a common cause of thrombophilia. Budd-Chiari syndrome, characterized by abdominal pain, ascites, and hepatomegaly, may require a thrombophilia screen to identify potential causes. Antithrombin deficiency, caused by a mutation in the SERPINC1 gene, is another type of thrombophilia. Antiphospholipid syndrome, an immunological disorder that increases the risk of thrombosis, is not related to Factor V Leiden mutations. Protein C deficiency, caused by mutations in the PROC gene, is another type of thrombophilia.

Understanding Factor V Leiden

Factor V Leiden is a common inherited thrombophilia, affecting around 5% of the UK population. It is caused by a mutation in the Factor V Leiden protein, resulting in activated factor V being inactivated 10 times more slowly by activated protein C than normal. This leads to activated protein C resistance, which increases the risk of venous thrombosis. Heterozygotes have a 4-5 fold risk of venous thrombosis, while homozygotes have a 10 fold risk, although the prevalence of homozygotes is much lower at 0.05%.

Despite its prevalence, screening for Factor V Leiden is not recommended, even after a venous thromboembolism. This is because a previous thromboembolism itself is a risk factor for further events, and specific management should be based on this rather than the particular thrombophilia identified.

Other inherited thrombophilias include Prothrombin gene mutation, Protein C deficiency, Protein S deficiency, and Antithrombin III deficiency. The table below shows the prevalence and relative risk of venous thromboembolism for each of these conditions.

Overall, understanding Factor V Leiden and other inherited thrombophilias can help healthcare professionals identify individuals at higher risk of venous thrombosis and provide appropriate management to prevent future events.

Condition | Prevalence | Relative risk of VTE
— | — | —
Factor V Leiden (heterozygous) | 5% | 4
Factor V Leiden (homozygous) | 0.05% | 10
Prothrombin gene mutation (heterozygous) | 1.5% | 3
Protein C deficiency | 0.3% | 10
Protein S deficiency | 0.1% | 5-10
Antithrombin III deficiency | 0.02% | 10-20

Understanding Sickle-Cell Anaemia

Sickle-cell anaemia is a genetic disorder that occurs when an abnormal haemoglobin chain, known as HbS, is synthesized due to an autosomal recessive condition. This condition is more common in people of African descent, as the heterozygous condition offers some protection against malaria. In the UK, around 10% of Afro-Caribbean individuals are carriers of HbS. Symptoms in homozygotes typically do not develop until 4-6 months when the abnormal HbSS molecules take over from fetal haemoglobin.

The pathophysiology of sickle-cell anaemia involves the substitution of the polar amino acid glutamate with the non-polar valine in each of the two beta chains (codon 6) of haemoglobin. This substitution decreases the water solubility of deoxy-Hb, causing HbS molecules to polymerize and sickle in the deoxygenated state. HbAS patients sickle at p02 2.5 – 4 kPa, while HbSS patients sickle at p02 5 – 6 kPa. Sickle cells are fragile and can cause haemolysis, block small blood vessels, and lead to infarction.

To diagnose sickle-cell anaemia, haemoglobin electrophoresis is the definitive test. It is essential to understand the pathophysiology and symptoms of sickle-cell anaemia to provide appropriate care and management for affected individuals.

As long as the patient’s Hb level is 7 or higher, transfusion may not be necessary for their management. However, this threshold may vary depending on individual factors such as co-existing medical conditions. It is important to avoid using old blood during massive transfusions as its effectiveness may be compromised.

Blood Products and Cell Saver Devices

Blood products are essential in various medical procedures, especially in cases where patients require transfusions due to anaemia or bleeding. Packed red cells, platelet-rich plasma, platelet concentrate, fresh frozen plasma, and cryoprecipitate are some of the commonly used whole blood fractions. Fresh frozen plasma is usually administered to patients with clotting deficiencies, while cryoprecipitate is a rich source of Factor VIII and fibrinogen. Cross-matching is necessary for all blood products, and cell saver devices are used to collect and re-infuse a patient’s own blood lost during surgery.

Cell saver devices come in two types, those that wash the blood cells before re-infusion and those that do not. The former is more expensive and complicated to operate but reduces the risk of re-infusing contaminated blood. The latter avoids the use of donor blood and may be acceptable to Jehovah’s witnesses. However, it is contraindicated in malignant diseases due to the risk of facilitating disease dissemination.

In some surgical patients, the use of warfarin can pose specific problems and may require the use of specialised blood products. Warfarin reversal can be achieved through the administration of vitamin K, fresh frozen plasma, or human prothrombin complex. Fresh frozen plasma is used less commonly now as a first-line warfarin reversal, and human prothrombin complex is preferred due to its rapid action. However, it should be given with vitamin K as factor 6 has a short half-life.

DIC, also known as consumptive coagulopathy, is a condition where the coagulation cascade is overactivated, leading to unchecked bleeding. This is due to the depletion of clotting mechanisms. Normally, clot formation and breakdown are balanced, with thrombin playing a key role in both processes. In DIC, patients may have prolonged coagulation times, thrombocytopenia, high levels of fibrin degradation products, elevated D-dimer levels, and microangiopathic pathology on peripheral smears. The excess fibrin strands in the intravascular circulation cause mechanical damage to red blood cells, resulting in schistocyte formation, thrombocytopenia, and consumption of clotting factors. Bite cells are abnormally shaped red blood cells with semicircular portions removed from the cell margin, seen in G6PD deficiency. Dacrocytes are teardrop-shaped cells seen in myelofibrosis and marrow disorders, while elliptocytes are red cells varying in shape from elongated to oval, seen in various disorders.

Disseminated Intravascular Coagulation: A Condition of Simultaneous Coagulation and Haemorrhage

Disseminated intravascular coagulation (DIC) is a medical condition characterized by simultaneous coagulation and haemorrhage. It is caused by the initial formation of thrombi that consume clotting factors and platelets, ultimately leading to bleeding. DIC can be caused by various factors such as infection, malignancy, trauma, liver disease, and obstetric complications.

Clinically, bleeding is usually the dominant feature of DIC, accompanied by bruising, ischaemia, and organ failure. Blood tests can reveal prolonged clotting times, thrombocytopenia, decreased fibrinogen, and increased fibrinogen degradation products. The treatment of DIC involves addressing the underlying cause and providing supportive management.

In summary, DIC is a serious medical condition that requires prompt diagnosis and management. It is important to identify the underlying cause and provide appropriate treatment to prevent further complications. With proper care and management, patients with DIC can recover and regain their health.

Iron deficiency anaemia is a prevalent condition worldwide, with preschool-age children being the most affected. The lack of iron in the body leads to a decrease in red blood cells and haemoglobin, resulting in anaemia. The primary causes of iron deficiency anaemia are excessive blood loss, inadequate dietary intake, poor intestinal absorption, and increased iron requirements. Menorrhagia is the most common cause of blood loss in pre-menopausal women, while gastrointestinal bleeding is the most common cause in men and postmenopausal women. Vegans and vegetarians are more likely to develop iron deficiency anaemia due to the lack of meat in their diet. Coeliac disease and other conditions affecting the small intestine can prevent sufficient iron absorption. Children and pregnant women have increased iron demands, and the latter may experience dilution due to an increase in plasma volume.

The symptoms of iron deficiency anaemia include fatigue, shortness of breath on exertion, palpitations, pallor, nail changes, hair loss, atrophic glossitis, post-cricoid webs, and angular stomatitis. To diagnose iron deficiency anaemia, a full blood count, serum ferritin, total iron-binding capacity, transferrin, and blood film tests are performed. Endoscopy may be necessary to rule out malignancy, especially in males and postmenopausal females with unexplained iron-deficiency anaemia.

The management of iron deficiency anaemia involves identifying and treating the underlying cause. Oral ferrous sulfate is commonly prescribed, and patients should continue taking iron supplements for three months after the iron deficiency has been corrected to replenish iron stores. Iron-rich foods such as dark-green leafy vegetables, meat, and iron-fortified bread can also help. It is crucial to exclude malignancy by taking an adequate history and appropriate investigations if warranted.

Understanding Antithrombin III Deficiency

Antithrombin III deficiency is a genetic condition that affects approximately 1 in 3,000 people. It is inherited in an autosomal dominant manner. This condition occurs when the body does not produce enough antithrombin III, a protein that helps to prevent blood clots by inhibiting certain clotting factors. Some patients with this deficiency have a shortage of normal antithrombin III, while others produce abnormal antithrombin III.

People with antithrombin III deficiency are at an increased risk of developing recurrent venous thromboses, which are blood clots that form in the veins. While arterial thromboses can also occur, they are less common. To manage this condition, patients may need to take warfarin for the rest of their lives to prevent thromboembolic events. During pregnancy, heparin may be used instead. Antithrombin III concentrates may also be used during surgery or childbirth.

It is important to note that patients with antithrombin III deficiency have a degree of resistance to heparin, so anti-Xa levels should be monitored carefully to ensure adequate anticoagulation. Compared to other inherited thrombophilias, antithrombin III deficiency is less common but has a higher relative risk of venous thromboembolism. Understanding this condition and its management is crucial for those affected and their healthcare providers.

Apixaban is a medication that directly inhibits factor Xa, which is responsible for the conversion of prothrombin to thrombin in the coagulation cascade. It is used as prophylaxis against embolic events in patients with atrial fibrillation, who are at increased risk due to blood pooling in the atria and potential clot formation. Unlike heparin, which activates antithrombin III to reduce blood clotting, apixaban works independently of antithrombin III. It also does not directly inhibit thrombin, which is the mechanism of action of dabigatran. Antiplatelets, such as aspirin and clopidogrel, work to decrease platelet activation and aggregation, but are not recommended for reducing the risks of embolic events in AF. Apixaban also does not inhibit vitamin K, which is the mechanism of action of warfarin.

Direct oral anticoagulants (DOACs) are medications used to prevent stroke in non-valvular atrial fibrillation (AF), as well as for the prevention and treatment of venous thromboembolism (VTE). To be prescribed DOACs for stroke prevention, patients must have certain risk factors, such as a prior stroke or transient ischaemic attack, age 75 or older, hypertension, diabetes mellitus, or heart failure. There are four DOACs available, each with a different mechanism of action and method of excretion. Dabigatran is a direct thrombin inhibitor, while rivaroxaban, apixaban, and edoxaban are direct factor Xa inhibitors. The majority of DOACs are excreted either through the kidneys or the liver, with the exception of apixaban and edoxaban, which are excreted through the feces. Reversal agents are available for dabigatran and rivaroxaban, but not for apixaban or edoxaban.

Tranexamic acid prevents major haemorrhage by binding to plasminogen and preventing plasmin from breaking down fibrin clots. Its mechanism of action is not related to increasing the availability of vitamin K or inhibiting anticlotting factors protein C and S. Similarly, reducing the availability of vitamin K would not be the mechanism of action of tranexamic acid. While stimulating anticlotting factors protein C and S would maintain clots, it is not the mechanism of action of tranexamic acid.

Understanding Tranexamic Acid

Tranexamic acid is a synthetic derivative of lysine that acts as an antifibrinolytic. Its primary function is to bind to lysine receptor sites on plasminogen or plasmin, preventing plasmin from degrading fibrin. This medication is commonly prescribed to treat menorrhagia.

In addition to its use in treating menorrhagia, tranexamic acid has been investigated for its role in trauma. The CRASH 2 trial found that administering tranexamic acid within the first 3 hours of bleeding trauma can be beneficial. In cases of major haemorrhage, tranexamic acid is given as an IV bolus followed by an infusion.

Ongoing research is also exploring the potential of tranexamic acid in treating traumatic brain injury. Overall, tranexamic acid is a medication with important applications in managing bleeding disorders and trauma.